The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DSKYF | -27.98% | -37.67% | -9.01% | +171% |
| S&P | +13.95% | +78.35% | +12.25% | +441% |
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
No news articles found for Daiichi Sankyo,.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.62B | 13.8% |
| Gross Profit | $2.85B | 22.0% |
| Gross Margin | 78.81% | 5.3% |
| Market Cap | $39.80B | -21.1% |
| Market Cap / Employee | $2.01M | 0.0% |
| Employees | 19.8K | 5.5% |
| Net Income | $562.29M | 38.4% |
| EBITDA | $708.35M | 36.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.45B | -20.4% |
| Accounts Receivable | $4.44B | 11.8% |
| Inventory | 4.2K | 37.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.91B | 197.9% |
| Short Term Debt | $2.57M | 0.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 8.78% | 1.6% |
| Return On Invested Capital | 8.96% | 1.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $348.50M | 39.3% |
| Operating Free Cash Flow | $527.89M | 34.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 22.93 | 22.06 | 22.31 | 19.51 | -40.23% |
| Price to Book | 4.01 | 3.78 | 3.82 | 3.56 | -20.01% |
| Price to Sales | 3.57 | 3.37 | 3.13 | 2.89 | -34.52% |
| Price to Tangible Book Value | 5.13 | 4.80 | 4.87 | 4.49 | -18.36% |
| Price to Free Cash Flow TTM | 20.26 | 26.29 | 23.45 | - | |
| Enterprise Value to EBITDA | 61.19 | 51.74 | 92.04 | 53.69 | -42.81% |
| Free Cash Flow Yield | 4.9% | 3.8% | 4.3% | - | |
| Return on Equity | 17.6% | 18.3% | 16.7% | 19.1% | 27.84% |
| Total Debt | $1.04B | $1.39B | $1.36B | $1.92B | 197.10% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
